A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Gene Expression Regulation, Developmental
  • Membrane Proteins
  • Neoplasm Proteins
  • Placenta
  • Trophoblasts

abstract

  • Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.

publication date

  • February 1993

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00873911

PubMed ID

  • 8349436

Additional Document Info

start page

  • 53

end page

  • 6

volume

  • 11

number

  • 1